Publications by authors named "Justin Koteff"

Claim this Profile
H
HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review.
Rickesh Patel, Lee Evitt, Ilias Mariolis, Simona Di Giambenedetto, Antonella d'Arminio Monforte, Justin Koteff

Infect Dis Ther· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
Joseph Eron, Chien-Ching Hung, Jean-Guy Baril, Jihad Slim, Vicenç Falcó, Justin Koteff

J Acquir Immune Defic Syndr· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.
Marta Boffito, Laura Waters, Pedro Cahn, Roger Paredes, Justin Koteff

AIDS Res Hum Retroviruses· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection.
Romina Quercia, Carlo-Federico Perno, Justin Koteff, Katy Moore, Cynthia McCoig

J Acquir Immune Defic Syndr· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
Benoît Trottier, Jordan E Lake, Ken Logue, Cynthia Brinson, Lizette Santiago, Justin A Koteff

Antivir Ther· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
Benoît Trottier, Jordan E Lake, Ken Logue, Cynthia Brinson, Lizette Santiago, Justin A Koteff

Antivir Ther· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects.
Justin Koteff, Julie Borland, Shuguang Chen, Ivy Song, Amanda Peppercorn

Br J Clin Pharmacol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis